CRIS Current Research Information System

GATTI, MILO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.966
EU - Europa 5.200
NA - Nord America 4.312
SA - Sud America 498
AF - Africa 234
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 18.252
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.180
IT - Italia 2.830
SG - Singapore 2.283
CN - Cina 2.278
VN - Vietnam 1.626
HK - Hong Kong 483
NL - Olanda 441
DE - Germania 396
KR - Corea 393
BR - Brasile 352
IN - India 315
SE - Svezia 244
FR - Francia 237
GB - Regno Unito 225
FI - Finlandia 171
RU - Federazione Russa 168
JP - Giappone 152
IE - Irlanda 111
CI - Costa d'Avorio 103
ID - Indonesia 84
CA - Canada 71
AR - Argentina 66
BG - Bulgaria 61
CH - Svizzera 56
ES - Italia 51
PH - Filippine 47
AT - Austria 45
PL - Polonia 45
TH - Thailandia 40
MX - Messico 39
BD - Bangladesh 36
TR - Turchia 34
IQ - Iraq 33
AU - Australia 32
TG - Togo 32
ZA - Sudafrica 29
TW - Taiwan 27
SA - Arabia Saudita 25
UA - Ucraina 22
JO - Giordania 19
PE - Perù 19
PK - Pakistan 18
EC - Ecuador 15
BE - Belgio 14
NG - Nigeria 14
CL - Cile 12
CO - Colombia 12
HR - Croazia 12
UZ - Uzbekistan 12
MY - Malesia 10
PT - Portogallo 10
PY - Paraguay 10
RO - Romania 10
IL - Israele 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 7
EG - Egitto 7
GR - Grecia 7
KE - Kenya 7
LT - Lituania 7
NP - Nepal 7
SC - Seychelles 7
VE - Venezuela 7
DZ - Algeria 6
JM - Giamaica 6
CY - Cipro 5
HU - Ungheria 5
IR - Iran 5
MA - Marocco 5
DK - Danimarca 4
NZ - Nuova Zelanda 4
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SM - San Marino 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CV - Capo Verde 2
EU - Europa 2
GH - Ghana 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
ME - Montenegro 2
MK - Macedonia 2
MT - Malta 2
PR - Porto Rico 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AQ - Antartide 1
BW - Botswana 1
BY - Bielorussia 1
Totale 18.229
Salva come PNG Salva come JPEG
Città #
Singapore 1.602
Hefei 866
Ashburn 605
Hong Kong 458
Ho Chi Minh City 440
Bologna 432
Seoul 367
San Jose 365
Hanoi 346
Santa Clara 324
Milan 286
Chandler 256
Beijing 209
Rome 201
Boardman 148
Lauterbourg 140
Los Angeles 138
Dallas 128
Tokyo 121
Princeton 118
Council Bluffs 110
Dublin 109
Abidjan 103
Southend 103
Helsinki 99
New York 99
Fairfield 98
Bengaluru 84
Dong Ket 83
Da Nang 68
Florence 63
Turin 63
Sofia 61
Redmond 60
Haiphong 59
Redondo Beach 57
Jakarta 55
Lappeenranta 53
Naples 53
Buffalo 51
Seattle 45
Chicago 44
Nuremberg 44
Genoa 42
Houston 42
Castel Maggiore 41
São Paulo 41
Frankfurt am Main 39
Munich 34
Bern 33
Shanghai 33
Lomé 32
Des Moines 30
London 30
Verona 30
The Dalles 29
Woodbridge 29
Berlin 28
Cambridge 27
Guangzhou 27
Toronto 27
Warsaw 27
Bari 26
Modena 26
Orem 26
Falkenstein 25
Vienna 25
Mumbai 24
Vicenza 24
Wilmington 24
Tongling 23
Amsterdam 22
Boydton 20
Padua 20
San Diego 20
Tappahannock 20
Biên Hòa 19
Bremen 19
Trieste 19
Amman 18
Turku 18
Xi'an 18
Can Tho 17
Denver 17
Montreal 17
Quận Bình Thạnh 17
Atlanta 16
Hải Dương 16
Baghdad 15
Bangkok 15
Hangzhou 15
Paris 15
Tianjin 15
Ann Arbor 14
Boston 14
Brisbane 14
Catania 14
Chengdu 14
Chennai 14
Lecce 14
Totale 10.544
Salva come PNG Salva come JPEG
Nome #
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 348
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 310
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 308
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 305
Artificial Intelligence model to predict resistances in Gram-negative bloodstream infections 253
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 244
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 239
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 214
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 194
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 193
Advances in the therapy of bacterial bloodstream infections 191
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 188
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 187
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 185
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 184
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 179
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 177
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 175
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 174
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 172
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 172
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 172
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 170
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 169
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 169
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 168
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 165
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 165
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 164
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 164
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 164
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 162
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 162
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 159
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 157
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 157
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 153
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 152
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 151
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 148
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 146
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 145
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 144
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 144
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 144
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 143
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 143
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 141
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 140
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 139
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 138
The European List of Key Medicines for Medical Education: A Modified Delphi Study 135
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 135
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 134
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 134
Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria 134
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 134
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 134
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 134
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review 133
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 132
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 131
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 131
Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems 130
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 128
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 127
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 126
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 125
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization 125
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 124
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment 122
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 122
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 121
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 121
Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues 120
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 119
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring 119
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 118
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring 118
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient 117
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan 116
Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements 116
Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda 116
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients 112
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 111
Clinical efficacy of renal dosing adjustments of ceftazidime‐avibactam in patients affected by carbapenem‐resistant Gram‐negative infections: a systematic review and meta‐analysis of observational studies 111
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT 109
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 107
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae 105
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis 105
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 105
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections 105
Role of a TDM-guided strategy of isavuconazole for optimizing efficacy/safety outcomes in onco-hematological pediatric patients: a systematic review 103
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia? 103
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections 102
Drug Interactions with Contraceptives 102
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections 100
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia 100
Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs 100
Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap 100
Totale 15.041
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021205 0 0 0 0 0 0 0 0 0 14 42 149
2021/20221.092 57 1 23 47 87 65 120 127 57 96 230 182
2022/20231.455 97 105 75 181 144 106 95 126 243 84 84 115
2023/20241.469 95 108 99 144 129 160 140 144 100 123 113 114
2024/20254.778 182 455 404 380 548 263 501 238 173 446 435 753
2025/20269.554 968 1.246 1.041 915 854 434 1.426 408 1.647 615 0 0
Totale 18.766